Introduction: Transcription of RNA from DNA-an essential step for gene expression and cellular function-is carried out by polymerases, which are essential enzymes. Unchecked cell proliferation, aberrant gene activity, and metastasis are all consequences of poor control of these enzymes in cancer. This review examines the causes of RNA polymerase dysregulation in cancer, assesses the therapeutic potential of transcription inhibitors, and talks about the difficulties encountered in their clinical development. Methods: The article reviews techniques for evaluating RNA polymerase inhibitors and examines research on RNA polymerase deficits in cancer. Drug selectivity, resistance mechanisms, toxicity to normal cells, and preclinical data supporting clinical usage are important considerations. Findings: Tumor suppressor genes can be suppressed, and oncogene activity can be increased by elevated or overactivated RNA polymerases, which can accelerate the development of cancer. By specifically eliminating cancer cells and stopping oncogenic transcription, RNA polymerase inhibitors have demonstrated encouraging preclinical outcomes. Discussion: RNA polymerases are appealing therapeutic targets since malignancies rely significantly on transcription. Clinical effectiveness depends on increasing medication selectivity, reducing off-target effects, and overcoming resistance. Combining several inhibitors might increase efficacy. In conclusion, RNA polymerase targeting presents a viable strategy for cancer treatment. To optimize advantages, future research should focus on enhancing inhibitor selectivity, lowering toxicity, and creating combination therapies.
Suresh Waghamare (Wed,) studied this question.